CE INFORMATION
Oncology Nursing Conference
Saturday, December 7, 2024 | Virtual Live CE Conference
Broadcast starts at 8:00 AM CT
HOW TO CLAIM CREDIT
In order to obtain your CE certificates, please follow the steps below at the conclusion of the event:
- Step 1: Log In
Access the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.
If you do not know your password, follow the link to reset it. - Step 2: Complete Evaluations
Click the Evaluations link located in the gray navigation bar (under the event title). You will see a listing of the sessions. Click the blue Take Evaluation button and complete the evaluation form for each session you attended. - Step 3: View and Print Certificates
After you’ve completed the evaluations, click the Print Certificate button to view and print your CE certificates.
Advanced NSCLC: Empowering Nurses to Improve Patient Care
in Rural and Underserved Communities
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; and Regeneron Pharmaceuticals, Inc. This session is supported by an independent medical education grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
CREDIT AVAILABLE
- Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
TARGET AUDIENCE
This activity is designed specifically for nurse practitioners, nurses, and other nursing professionals who provide cancer care to patients from rural and underserved communities.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to:
- Describe current and emerging therapies for patients with advanced non-small cell lung cancer (NSCLC)
- Apply best practices for identifying, monitoring, and managing adverse events associated with therapies for NSCLC
- Integrate effective communication strategies and patient education to optimize outcomes in patients with advanced NSCLC
FACULTY
Marianne J. Davies, DNP, ACNP, AOCNP, FAAN
Program Manager, Care Signature Oncology Service Line
Oncology Nurse Practitioner
Yale-New Haven Hospital and Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, CT
Lance F. Ortega, MBA, BSN, RN, OCN
Executive Director, Clinical Operations
Texas Oncology
Dallas-Fort Worth, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Marianne J. Davies, DNP, ACNP, AOCNP, FAAN, has no relevant financial relationships to disclose.
Lance F. Ortega, MBA, BSN, RN, OCN, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
A Case-Based Approach to Managing Advanced NSCLC: Empowering Nurses
to Improve Patient Care in Rural and Underserved Communities
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; and Regeneron Pharmaceuticals, Inc. This session is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.
CREDIT AVAILABLE
- Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
TARGET AUDIENCE
This activity is designed specifically for nurse practitioners, nurses, and other nursing professionals who provide cancer care to patients from rural and underserved communities.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to:
- Describe current and emerging therapies for patients with advanced NSCLC
- Apply best practices for identifying, monitoring, and managing adverse events associated with therapies for NSCLC
- Integrate effective communication strategies and patient education to optimize outcomes in patients with advanced NSCLC
FACULTY
Marianne J. Davies, DNP, ACNP, AOCNP, FAAN
Program Manager, Care Signature Oncology Service Line
Oncology Nurse Practitioner
Yale-New Haven Hospital and Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, CT
Lance F. Ortega, MBA, BSN, RN, OCN
Executive Director, Clinical Operations
Texas Oncology
Dallas-Fort Worth, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Marianne J. Davies, DNP, ACNP, AOCNP, FAAN, has no relevant financial relationships to disclose.
Lance F. Ortega, MBA, BSN, RN, OCN, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Enhancing Oncology Nursing Care in Advanced Gastric/GEJ Cancers: Bridging Knowledge Gaps
in Biomarkers, Emerging Therapies, and Adverse Event Management
Provided by Talem Health and RME Collaborative:
ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Astellas; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; and Regeneron Pharmaceuticals, Inc. This session is supported by an independent medical education grant from Astellas.
CREDIT AVAILABLE
- Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
TARGET AUDIENCE
This activity is designed specifically for nurse practitioners, nurses, and other nursing professionals who provide cancer care to patients from rural and underserved communities.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to:
- Explain the role of biomarkers in gastric/gastroesophageal junction (GEJ) cancers to guide diagnosis and treatment decisions
- Describe the mechanism of action of emerging systemic therapies for unresectable locally advanced or metastatic gastric/GEJ cancers
- Evaluate clinical evidence on the safety and efficacy of current and emerging systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers
- Implement team-based strategies for monitoring and managing adverse events associated with systemic therapies for locally advanced unresectable or metastatic gastric/GEJ cancers
FACULTY
Nina N. Grenon, DNP, AOCN
Nurse Practitioner
Gastrointestinal Oncology
Dana-Farber Cancer Institute
Center for Gastrointestinal Oncology
Boston, MA
Lance F. Ortega, MBA, BSN, RN, OCN
Executive Director, Clinical Operations
Texas Oncology
Dallas-Fort Worth, TX
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Nina N. Grenon, DNP, AOCN, has disclosed the following relevant financial relationships: consultant/advisory board member for Astellas.
Lance F. Ortega, MBA, BSN, RN, OCN, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT US
For questions about this program, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.
MEDIA
Internet activity
COMPUTER SYSTEM REQUIREMENTS
- System checker: Must meet all requirements of BroadcastMed Live Events Platform
- Operating system: Windows or Macintosh
- Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
- Hardware: computer, smartphone, or tablet
- Broadband Internet connection: high-speed connection preferable
FEE INFORMATION
There is no fee for this educational activity.
COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.
